immunoglobulins
ApprovedSmall molecule
CSL Behringimmunoglobulins is one of 330 small molecule programs targeting Chronic Inflammatory Demyelinating Polyneuropathy. It is currently in Approved.
11
Indications
24
Total Trials
5
Active Trials
329
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 11 indications
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1immunoglobulins
CSL BehringApproved
Singulair
AstraZenecaPreclinical
Proventil
Mylan Pharmaceuticals IncPreclinical
Nadroparin
GSKPreclinical
Biological Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
Antihypertensive Agents
NNational Heart, Lung, and Blood Institute (NHLBI)
Preclinical
Antithrombin-III
OctapharmaPreclinical
Selenium
SSWOG Cancer Research Network
Preclinical
COVID-19 Vaccines
UUniversity of British Columbia
Preclinical
Netakimab
SSPH-BIOCAD (HK) Limited
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Primary Immunodeficiencies3 trials
COVID-191 trial
Antibiotic Therapy1 trial
16 more indications
Hepatitis B1 trial
Renal Transplant Recipients1 trial
Encephalitis1 trial
Cardiomyopathy1 trial
Kidney Transplant1 trial
Urticaria1 trial
Intravenous Immunoglobulins in Severe and Refractory Solar Urticaria
Completed·—·Phase 2·NCT01360658·10 enrolled
Chronic Inflammatory Demyelinating Polyneuropathy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for immunoglobulins. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company